Search

everythinglearnresearchcommunity

for

Search:↓

The user healthydudenextdoor starting a new topical anti-androgen hair loss treatment, Pyrilutamide, and discussing their current regimen of finasteride and minoxidil.

Ultrasound imaging can predict hair shedding and assess hair growth stages by analyzing hair follicle characteristics. The conversation also discusses using ultrasound for personal hair analysis and mentions the potential use of infrared emission for hair treatment.

FLEAVA is accused of scamming customers by enrolling them in unwanted monthly subscriptions for Advanced Copper Peptide without consent. Many users struggled to get refunds and reported ongoing charges despite cancellation requests.

The results of using Pyrilutamide, a hair loss treatment available on the gray market, and other treatments such as Minoxidil, Finasteride and RU58841.

Hair cloning technology is advancing, with clinical trials for improved methods expected by 2028 and 2029, potentially offering a solution for hair loss if donor follicles remain. Organtech's expansion into other biotech areas may secure funding, but the effectiveness of cloning depends on the availability of androgen-resistant donor follicles.

The conversation discusses the effectiveness of RU58841 and pyrilutamide for hair loss treatment. It seeks personal success or failure stories and scientific data on these treatments.

A user's journey with hair loss and their use of topical finasteride, minoxidil and pyri/minoxidil ratio treatments to attempt hair regrowth. Replies focused on offering support and advice while sharing personal experiences with different treatments.

Minoxidil without propylene glycol is sought to avoid dermatitis, with Rogaine foam and Tecflox suggested as alternatives. Users discuss using foam to prevent irritation and suggest heating it for easier application.

The user is considering using Ruderma to maintain hair and is concerned about potential hair loss acceleration due to starting TRT. They are also inquiring about the use of minoxidil, RU58841, and a derma roller for hair maintenance.

The conversation is about using RU58841 and microneedling (1.5mm) for hair loss. The user seeks advice on whether to avoid applying RU58841 on microneedling days to prevent it from becoming systemic.

A 27-year-old male experiencing hair loss post-Covid is considering PRP (platelet-rich plasma) therapy. He's seeking personal experiences about the process, particularly regarding pain levels, despite his dermatologist's assurance of using local anesthesia.

User saw new hair growth after 2 months of treatment. Others shared similar experiences and joked about hair soldiers reclaiming lost territory.

Stem-cell hair transplants could potentially create thousands of grafts from a single donor graft, offering a solution for hair loss with DHT-resistant hair. Companies like Stemson Therapeutics and OrganTech are working on this technology, which may become available in the future, possibly reducing the cost and making it widely accessible.

User used topical minoxidil 5% with 0.1% finasteride twice daily, oral minoxidil 2.5mg, and finasteride 1mg daily, along with a hair multivitamin and weekly derma rolling. They missed the medication 3-4 times but still saw significant progress.

A user experiencing aggressive hair loss is considering starting treatment with finasteride and minoxidil. Others suggest various treatments including dutasteride, topical minoxidil with finasteride, and microneedling, with mixed experiences and emphasis on not delaying treatment.

The conversation discusses the use of Verteporfin in hair loss treatment. It suggests that Verteporfin could potentially regenerate hair follicles instead of forming scars, providing an unlimited donor supply for hair transplants.

Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.

A user was recommended PRP and exosomes for hair loss and asked about combining them and places to get the treatment in the UK. Other users suggested starting with finasteride and minoxidil due to the high cost and variable success of PRP and exosomes.

PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.

The user experienced significant hair regrowth using Minoxidil (Rogaine) and dermarolling twice a week. They also lost weight and improved their diet, which may have contributed to the results.

A 36-year-old started using finasteride (0.3-0.5mg daily), 5% minoxidil foam, and weekly dermarolling/dermapen treatments to address hair loss. They also began taking supplements for low ferritin and vitamin D, hoping to improve hair thickness and cover a bald spot.

A new hair loss treatment, KX-826, is being discussed as a stronger and safer alternative to RU58841 and finasteride. Opinions are mixed, with some users skeptical about its effectiveness and others considering it as part of their regimen.

The user experienced improved self-confidence and hair regrowth using finasteride, minoxidil, and dermarolling. Visible results were noted after about three months, with microneedling done once a week.

Dermastamps are preferred over dermarollers for microneedling due to precision and reduced risk of scarring. Dermastamps allow for controlled, vertical needle entry, while dermarollers may cause more damage with sideways needle entry.

The user started using a hair loss treatment regimen including 5% minoxidil spray twice daily, 1% finasteride spray once daily, microneedling weekly, and ketoconazole shampoo twice a week, experiencing significant hair shedding. The shedding is seen as a positive sign, indicating hair follicles are entering a new growth phase.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

A user successfully regrew hair using 1mg finasteride, switching to 0.5mg dutasteride, and maintaining 5mg oral minoxidil, with significant improvements noted after switching to dutasteride. The user experienced shedding phases but ultimately achieved regrowth and is now comfortable without wearing a hat.

The conversation is about skepticism regarding new hair loss treatments until they are FDA approved. People have been joking about treatments being 5-7 years away for decades.

This user has had success with Minoxidil foam, achieving significant hair growth in three months without using finasteride or derma rolling. They are considering incorporating a DHT reducing strategy such as finasteride in the future.